Cell Phenotype-Based Activity Screening
Cell phenotype-based drug screening targets the overall function and behavior of cells (phenotype), focusing on the effects of drugs on characteristics such as cell growth, migration, apoptosis, differentiation, metabolism, and morphology, rather than targeting specific molecules. By utilizing high-throughput screening technologies and modern imaging techniques, researchers can quickly and accurately analyze large numbers of compounds, capturing complex cellular responses and providing more biologically relevant metrics for drug development.
MCE cell screening platform features over 500 cell lines and multiple organoid culture systems, covering more than 30 tumor types. It offers multiple methods for assessing cell viability, apoptosis, and cell cycle, including WST-8, CTG assays, and flow cytometry. Additionally, it enables the detection of cytokines and gene expression through ELISA and qPCR, which can provide comprehensive support for researchers to analyze the cellular function and new drug development.
Services Offered
Cell Viability
Assays
Apoptosis Assays
Cell Cycle
Analysis
Cytokine
Detection
Gene Expression
Analysis
Organoid
Drug
Screening
Advantages
Abundant Cell Line
Resources
Diverse Detection
Methods
Advanced and Fully
Equipped Instruments
Customized, Cost-Effective Solutions
Stringent Data
Privacy Management
Cell Viability Assay
Cell viability refers to the ability of cells to maintain growth, reproduction, and physiological functions under both physiological and environmental conditions. It is closely related to the survival status, proliferative capacity, metabolic activity, and functional state of the cells. In cell biology research and drug development, cell viability serves as a critical assessment metric, as it reflects the health status of cells following exposure to various stimuli or drug treatments. This metric is widely used in fields such as anticancer drug screening and drug toxicity testing.
Common methods for assessing cell viability include WST-8 and CTG assays. By evaluating the effects of drugs on cell viability and proliferation, researchers can rapidly assess the anticancer effects and toxicity of potential drug candidates.
Apoptosis Assay
Apoptosis, also known as programmed cell death, is a gene-regulated process of active cell death that plays a vital role in normal biological development and disease resistance. Dysregulation of apoptosis is closely linked to the onset and progression of various diseases, including tumors, neurodegenerative disorders, and autoimmune diseases.
The process of cell apoptosis exhibits obvious morphological characteristics, including cell shrinkage, cell membrane phosphatidylserine (PS) eversion, protein cleavage, chromatin condensation, and internucleosome DNA fragmentation, which ultimately lead to the formation of apoptotic bodies. Using flow cytometry, apoptotic detection markers can be combined with cell phenotype markers, allowing for the observation of changes in cell subpopulations. By employing fluorescently labeled Annexin V as a fluorescent probe, along with nuclear stains such as PI, 7-AAD, and DAPI, researchers can accurately differentiate between normal cells, early apoptotic cells, late apoptotic, and necrotic cells.
Cell Cycle Analysis
The cell cycle consists of the interphase and the mitotic phase. Interphase is further subdivided into G0 phase, G1 phase, S phase, and G2 phase, while the mitotic phase is referred to as M phase. During interphase, the cell grows and its nuclear DNA is duplicated. Interphase is followed by the mitotic phase. During the mitotic phase, the duplicated chromosomes are segregated and distributed into daughter nuclei. One of the most common methods for detecting the cell cycle is to stain the DNA within cells using Propidium Iodide (PI) and measure DNA content with flow cytometry.
Organoid Drug Screening
Organoids are three-dimensional (3D) tissue-like structures that are formed through the in vitro culture of adult or pluripotent stem cells. Although organoids are not true human organs, they can closely mimic the structure and function of real organs and can be stably passed over long periods. Many organoids can undergo extensive expansion in culture while maintaining genomic stability, making them particularly suitable for drug screening. They provide a more physiologically relevant representation of cellular composition and behavior compared to traditional 2D cell cultures and have been widely utilized in the field of anticancer drug screening.
MCE continuously optimizes culturing methods and has successfully developed organoid culture systems that encompass various cancer types, including lung cancer, liver cancer, head and neck cancer, gastric cancer, and colorectal cancer. These organoid systems can be used to evaluate the efficacy of protein drugs or small molecules, thereby accelerating the drug development process.
MCE tumor cell lines (partial)
| Disease | Cell Line |
|---|---|
| Bladder cancer | 5637; 647V; HT1197; HT1376; J82; KU1919; RT112; RT4; SCaBER; SW1710; SW780; T24; TCCSUP; UMUC3; |
| Brain Cancer | A172; IMR32; KP-N-YN; LN18; LN229; NB1; SF268; SH-SY5Y; SK-N-AS; SK-N-BE(2); SK-N-SH; SW1088; U87 MG; U251 |
| Bone Cancer | SW1353; U2OS |
| Breast Cancer | BT20; BT474; BT483; CAL148; CAMA1; EFM19; HCC1187; HCC1395; HCC1419; HCC1500; HCC1569; HCC1599; HCC1806; HCC1937; HCC1954; HCC202; HCC2218; HCC38; HCC70; Hs578t; JimT1; MCF7; MDAMB157; MDAMB231; MDAMB361; MDAMB453; MDAMB468; SKBR3; SUM159; T47D; ZR751; |
| Cervical Cancer | C33A; CASKI; Hela; ME180; MS751; SiHa |
| Colorectal Cancer | Caco2; COLO201; COLO205; COLO320DM; COLO678; DLD1; GP2d; HCT116; HCT15; HCT8; HT29; LoVo; LS174T; LS513; NCIH508; NCIH747; RKO; SNU407; SW1116; SW403; SW48; SW480; SW620; SW837; WiDR |
| Duodenal Cancer | Hutu80 |
| Endometrial Cancer | AN3CA; HEC1A; HEC1B; MFE280; MFE296; RL95-2 |
| Esophageal Cancer | KYSE520 |
| Gastric Cancer | AGS; Hs746T; KATOIII; MKN1; MKN45; NCIN87; NUGC3; NUGC4; OCUM1; SNU1; SNU16; SNU5; SNU620; SNU668 |
| Head and Neck Cancer | CAL27; SCC9 |
| Kidney Cancer | 293T; 786o; A498; ACHN; Caki2; G401 |
| Laryngeal Cancer | SNU899 |
| Leukemia | CCRFCEM; HL60; HPB ALL; Jurkat; K562; Kasumi1; Kasumi6; KG1; KOPN8; ML2; MOLM13; MOLT4; MV411; NALM6; RS411; SKM1; THP1; U937 |
| Liver Cancer | HEP3B; HepG2; HLE; HUH7; JHH7; MHCC97L; PLC/PRF/5; SKHEP1; SNU182 |
| Lung Cancer | A427; A549; BEAS-2B; CAL12T; Calu1; Calu3; Calu6; DMS114; DMS53; EBC1; HCC2935; HCC4006; HCC827; MSTO211H; NCIH1048; NCIH1092; NCIH1299; NCIH1395; NCIH146; NCIH1563; NCIH1573; NCIH1581; NCIH1650; NCIH1666; NCIH1792; NCIH1836; NCIH1882; NCIH1930; NCIH1944; NCIH1975; NCIH2009; NCIH2052; NCIH209; NCIH211; NCIH2110; NCIH2122; NCIH2228; NCIH226; NCIH2452; NCIH292; NCIH3122; NCIH322; NCIH358; NCIH441; NCIH446; NCIH460; NCIH520; NCIH522; NCIH524; NCIH526; NCIH647; NCIH661; NCIH69; NCIH838; NCIH841; NCIH889; PC9; SHP77; SKLU1; SKMES1; WI38 |
| Lymphoma | Daudi; DOHH2; Farage; H9; HUT102; Hut78; JeKo1; Karpas299; Karpas422; MAVER1; Mino; Namalwa; OCILY1; OCILY19; Pfeiffer; Raji; Ramos(RA-1); REC1; SR; SUDHL1; SUDHL6; SUDHL8; SUDHL10; Toledo; U2932; WSUDLCL2; Z138 |
| Myeloma | KMS11; KMS34; MM1S; MOLP8; NCIH929; RPMI8226; U266B1 |
| Ovary Cancer | A2780; CAOV3; ES2; IGROV1; MDAH2774; OV90; OVCAR3; OVCAR8; PA1; RKN; RMG1; SKOV3; TOV112D; TOV21G; UWB1289 |
| Pancreas Cancer | ASPC1; BxPC3; Capan1; Capan2; HPAC; HPAFII; HUPT3; KP4; Miapaca2; PANC04.03; PANC1; PK59; PSN1; QGP1; SU.86.86; SW1990 |
| Papilloma | KB |
| Prostate Cancer | 22RV1; DU145; LNCap clone FGC; PC3 |
| Sarcoma | HT1080 |
| Skin Cancer | A375; A431; C32; G361; MDAMB435S; MeWo; SKMEL2; SKMEL5; SKMEL28; WM115 |
| Squamous Cell Carcinoma | UPCISCC090 |
| Thyroid Cancer | CAL62 |
MCE technicians have a wealth of experience, efficiently and accurately complete the various tests to ensure that the experimental data is accurate and reliable, and ultimately provide detailed and complete reports. We can also customize cost-effective solutions to meet specific needs. For more information regarding pricing or technical details, please email [email protected] or contact MCE sales directly.
Product Customization
-
Specific Compounds
-
Quantities
-
Plate Map
-
Concentration
-
Form (Solid or Solution)
-
YES